Eli Lilly and Co topped Wall Street estimates for third-quarter profit on Tuesday and raised its yearly earnings target, led by stronger demand for its newer drugs such as diabetes treatment Trulicity and psoriasis medicine Taltz.
Source:: Reuters – Business News
